Article ; Online: Dimethyl sulfoxide reduces the stability but enhances catalytic activity of the main SARS-CoV-2 protease 3CLpro.
2021 Volume 35, Issue 8, Page(s) e21774
Abstract: ... CoV-2 life cycle be identified and developed. 3-Chymotrypsin-like protease (3CLpro) is an attractive ... Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for coronavirus disease ... antiviral drug target against SARS-CoV-2, and coronaviruses in general, because of its role in the processing ...
| Abstract | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for coronavirus disease 2019 (COVID-19), one of the most challenging global pandemics of the modern era. Potential treatment strategies against COVID-19 are yet to be devised. It is crucial that antivirals that interfere with the SARS-CoV-2 life cycle be identified and developed. 3-Chymotrypsin-like protease (3CLpro) is an attractive antiviral drug target against SARS-CoV-2, and coronaviruses in general, because of its role in the processing of viral polyproteins. Inhibitors of 3CLpro activity are screened in enzyme assays before further development of the most promising leads. Dimethyl sulfoxide (DMSO) is a common additive used in such assays and enhances the solubility of assay components. However, it may also potentially affect the stability and efficiency of 3CLpro but, to date, this effect had not been analyzed in detail. Here, we investigated the effect of DMSO on 3CLpro-catalyzed reaction. While DMSO (5%-20%) decreased the optimum temperature of catalysis and thermodynamic stability of 3CLpro, it only marginally affected the kinetic stability of the enzyme. Increasing the DMSO concentration up to 20% improved the catalytic efficiency and peptide-binding affinity of 3CLpro. At such high DMSO concentration, the solubility and stability of peptide substrate were improved because of reduced aggregation. In conclusion, we recommend 20% DMSO as the minimum concentration to be used in screens of 3CLpro inhibitors as lead compounds for the development of antiviral drugs against COVID-19. |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| MeSH term(s) | COVID-19/virology ; Computer Simulation ; Coronavirus 3C Proteases/genetics ; Coronavirus 3C Proteases/metabolism ; Dimethyl Sulfoxide/pharmacology ; Gene Expression Regulation, Enzymologic/drug effects ; Gene Expression Regulation, Viral/drug effects ; Humans ; Microfluidic Analytical Techniques ; Peptides/metabolism ; Protein Stability ; SARS-CoV-2/enzymology | ||||||||||
| Chemical Substances | Peptides ; Coronavirus 3C Proteases (EC 3.4.22.28) ; Dimethyl Sulfoxide (YOW8V9698H) | ||||||||||
| Language | English | ||||||||||
| Publishing date | 2021-07-29 | ||||||||||
| Publishing country | United States | ||||||||||
| Document type | Journal Article ; Research Support, Non-U.S. Gov't | ||||||||||
| ZDB-ID | 639186-2 | ||||||||||
| ISSN | 1530-6860 ; 0892-6638 | ||||||||||
| ISSN (online) | 1530-6860 | ||||||||||
| ISSN | 0892-6638 | ||||||||||
| DOI | 10.1096/fj.202100994 | ||||||||||
| Shelf mark |
|
||||||||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 2266: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
|||
| Zs.MO 296: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.